Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CYP11B2 | P19099 | 4/20 | 0.43 |
| ▸ | MAPK13 | O15264 | 2/20 | 0.36 |
| ▸ | MAPK12 | P53778 | 2/20 | 0.36 |
| ▸ | MAPK11 | Q15759 | 2/20 | 0.36 |
| ▸ | MAPK14 | Q16539 | 2/20 | 0.36 |
| ▸ | BRD4 | O60885 | 2/20 | 0.33 |
| ▸ | SIGMAR1 | Q99720 | 1/20 | 0.33 |
| ▸ | GABRG2 | P18507 | 4/20 | 0.32 |
| ▸ | GABRB3 | P28472 | 4/20 | 0.32 |
| ▸ | GABRA5 | P31644 | 4/20 | 0.32 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.32 |
| ▸ | TGFBR1 | P36897 | 1/20 | 0.31 |
| ▸ | TGFBR2 | P37173 | 1/20 | 0.31 |
| ▸ | HSD17B13 | Q7Z5P4 | 1/20 | 0.30 |
| ▸ | BAZ2A | Q9UIF9 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19035767 | 0.77 | GDA (0.30) | — | |
| SCHEMBL21527507 | 0.74 | BRD4 (0.35) | BRD4 | |
| SCHEMBL20105842 | 0.73 | CYP11B2 (0.42) | CYP11B2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL20206036 | 0.72 | HCAR3 (0.32) | TGFBR1TGFBR2 | |
| SCHEMBL21316872 | 0.69 | CYP11B2 (0.42) | CYP11B2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL24611653 | 0.67 | CYP11B2 (0.38) | CYP11B2GABRG2GABRB3GABRA5 | |
| SCHEMBL19607616 | 0.67 | CYP11B2 (0.38) | CYP11B2GABRG2GABRB3GABRA5 | |
| SCHEMBL19607609 | 0.65 | CYP11B2 (0.34) | CYP11B2MAPK13MAPK12MAPK11MAPK14 | |
| SCHEMBL20205954 | 0.65 | CYP11B2 (0.47) | CYP11B2BRD4BAZ2A | |
| SCHEMBL19607694 | 0.65 | CYP11B2 (0.33) | CYP11B2MAPK13MAPK12MAPK11MAPK14 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | Guangdong Raynovent Biotech Co., Ltd. (CN) | 2018-05-31 | — | — | US | disclosed |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | GUANGDONG ZHONGSHENG PHARMACEUTICAL CO., LTD (CN) | 2017-11-16 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20180148451-A1 | HYDROXYL PURINE COMPOUNDS AND USE THEREOF | PNP, PDE7A, PDE2A | CYP11B2 77/4885MAPK13 1280/4885MAPK12 1163/4885 |
| US-20170326149-A1 | HYDROXYL PURINE COMPOUNDS AND APPLICATIONS THEREOF | PNP, PDE2A, PDE7A | CYP11B2 198/4885MAPK13 1863/4885MAPK12 1231/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.